Physician profile
Christine Simons
NPI 1497381701
$5,185.95
in general payments reported to CMS, 2019-2025
44 companies · $475 in 2025
The $475 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,757 · 2022: $1,201 · 2023: $1,455 · 2024: $298 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.09 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,786.01 | 2021-2025 | |
| Allergan, INC. | $390.50 | 2021-2022 | |
| Janssen Biotech, INC. | $243.61 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $234.76 | 2021-2025 | |
| Pfizer INC. | $227.81 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $217.50 | 2021 | |
| Csl Behring | $205.48 | 2021-2023 | Hizentra, Privigen |
| Biogen, INC. | $174.70 | 2021-2022 | |
| Amgen INC. | $151.59 | 2021-2024 | Aimovig, Otezla |
| Ucb, INC. | $137.01 | 2021 | |
| Lilly USA, LLC | $135.36 | 2021-2023 | Amyvid, Emgality, Reyvow |
| Lundbeck LLC | $109.78 | 2021-2023 | Vyepti |
| Genzyme Corporation | $103.98 | 2022-2023 | |
| Upsher-Smith Laboratories LLC | $86.87 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $86.04 | 2024-2025 | Libtayo, Dupixent |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Simons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.